Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients

Intersectionality of stigmas and health-related quality of life in people ageing with HIV in China, Europe, and Latin America

People ageing with HIV face crucial challenges that can compromise their long-term health, one of which is stigma. HIV-related stigma can interact with other coexistent inequities to create a unique oppression system that results in traumatic experiences. This intersectionality of stigmas represents a new inequality that is greater than the sum of the original component inequalities. In this Series paper we review the literature regarding the intersectionality of HIV-related and ageing-related stigma and health-related quality of life among people ageing with HIV in China, Europe, and Latin America-three regions that represent distinct epidemiological and cultural trends in terms of HIV and ageing. Substantial gaps in the literature were identified, in particular a scarcity of data from Latin America. We also found inconsistencies between countries in terms of definitions and reporting practices related to people ageing with HIV. Research that fully considers the intersectional stigmas faced by this vulnerable population will contribute to advancing the United Nations 2030 Agenda for Sustainable Development.

Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort

Introduction

Previous studies have reported better immunovirological characteristics in women compared with men after HIV seroconversion. We investigated whether differences persisted under long‐term antiretroviral therapy (ART) in individuals treated since acute and early HIV‐1 infection (AHI).

Methods

Data were obtained for 262 women and 1783 men enrolled between 1996 and 2017 in the French multicentre ANRS PRIMO cohort. We modelled the viral response, long‐term immune recovery and HIV DNA decay in the 143 women and 1126 men who initiated ART within the first three months of infection.

Results

The participants were mostly white. The mean age was 37 years at AHI diagnosis. Pre‐ART viral loads were lower in women than men, 5.2 and 5.6 log₁₀ copies/mL (p = 0.001). After ART initiation, women more rapidly achieved viral suppression than men (adjusted hazard ratio: 1.33, 95% confidence interval 1.09 to 1.69). They also experienced a faster increase in CD4⁺ T‐cell count and CD4:CD8 ratio during the first months of treatment. Sex‐related differences in CD4⁺ T‐cell counts were more pronounced with increasing age. This led to a sustained mean difference of 99 to 168 CD4⁺ T‐cells/µL depending on age between women and men at 150 months of ART. Moreover, CD4:CD8 ratio of women was higher than that of men by 0.31, at 150 months of ART. There was no statistically significant difference between sexes for the levels of HIV DNA over time (mean estimate at the last modelling point: 1.9 log₁₀ copies/10⁶ PBMCs after 70 months of ART for both sexes).

Conclusions

The high level of immune recovery and decrease in total HIV DNA levels achieved after ART initiation during AHI reinforce the importance of early diagnosis of HIV infection and immediate ART initiation. The immunological benefit of being female increased throughout prolonged ART duration, which may give women additional protection from adverse clinical events and premature ageing.

Immunological and Virological Responses in Older HIV-Infected Adults Receiving Antiretroviral Therapy: An Evidence-Based Meta-Analysis

BACKGROUND

Millions of people living with the HIV have received antiretroviral therapy (ART). Older adults make up a significant portion of these individuals; however, the immunological and virological responses to ART for older patients still need to be clarified.

DESIGN

Meta-analysis.

METHODS

In this article, we systematically reviewed research articles published between 2001 and 2018 that reported immunological and virological responses and AIDS-related mortality among HIV- infected adults (including individuals aged 50 years and older) receiving ART, using meta-analysis. ART efficiency was measured using 3 outcomes: (1) immunological response, (2) virological response, and (3) mortality.

RESULTS

We identified 4937 citations, and 40 studies were eventually selected to investigate ART efficiency in older HIV-infected patients, comprising more than 888,151 patients initiating ART. We report that older patients showed poor immunological responses, with CD4 counts and the restoration of CD4 counts after ART initiation being significantly lower than seen in younger patients. However, older patients exhibited better viral suppression rates (risk ratio: 1.04; 95% confidence intervals: 1.01 to 1.08) after 36 months following ART initiation. In addition, older adults had a higher risk of AIDS-related death (adjusted hazard ratio: 1.44, 95% confidence interval: 1.30 to 1.60).

CONCLUSIONS

Older age after ART initiation was associated with a poorer immunological response and a higher risk of mortality, suggesting the need to increase early diagnosis and treatment among older HIV patients.

Immunologic and virologic responses to antiretroviral therapy in treatment-naïve, HIV-infected elderly patients

Currently available data on immunologic and virologic responses to antiretroviral therapy (ART) in elderly patients are conflicting. The primary objective of this study was to assess immunologic and virologic responses to ART in treatment-naïve, HIV-infected elderly patients compared to younger patients. This was a single center, retrospective, descriptive study including treatment-naïve, HIV-infected adults initiated on ART between 1 January 2005 and 30 April 2015. Immunologic and virologic responses were compared between the ages ≥50 and < 50 years old. A total of 158 patients were included. By 14 months of ART, 85.9% (n = 67/78) of the patients ≥50 years old and 92.5% (n = 74/80) of those < 50 years old achieved immunologic response (p = 0.02). By 24 weeks of ART, 64.1% (n = 50/78) of the patients ≥50 years old and 65% (n = 52/80) of those < 50 years old achieved virologic response (p = 1). The amount of time it took the elderly patients to achieve virologic suppression was not significantly different compared to the younger patients (p = 0.459). Treatment-naïve, HIV-infected elderly patients achieved virologic response to ART that was comparable to younger patients although their immunologic response to ART was significantly lower.